Detection methods of circulating tumor cells in cutaneous melanoma: A systematic review

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 1, 2014, Pages 74-92

  Rodic, Stefan ^a   Mihalcioiu, Catalin ^b   Saleh, Ramy R ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cancer; Circulating tumor cells; Cutaneous melanoma; Detection; Systematic review

Indexed keywords

BETA 1,4 N ACETYL GALACTOSAMINYL TRANSFERASE; CD146 ANTIGEN; COMPLEMENTARY DNA; MELAN A; MELANOMA ANTIGEN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; TRANSCRIPTION FACTOR PAX3; TUMOR MARKER; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL EVALUATION; CUTANEOUS MELANOMA; CYTOLOGY; CYTOMETRY; DISEASE ASSOCIATION; DNA SYNTHESIS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HOUSEKEEPING GENE; HUMAN; IMMUNOCYTOMETRY; IMMUNOMAGNETIC SEPARATION; INTERMETHOD COMPARISON; MELANOMA CELL; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA DEGRADATION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; MELANOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR EMBOLISM;

HUMANS; MELANOMA; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION;

EID: 84901640516     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.01.007     Document Type: Review

References (154)

1. Jerant A.F., Johnson J.T., Sheridan C.D., Caffrey T.J. Early detection and treatment of skin cancer. American Family Physician 2000, 62. p. 357-368, 375-356, 381-352.
2. Cancer facts & figures 2013. (ed. Society, A.C.).(Atlanta 2013).
3. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001, 19:3635-3648.
4. Tsao H., Cosimi A.B., Sober A.J. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997, 79:2361-2370.
5. Crowley N.J., Seigler H.F. Late recurrence of malignant melanoma. Analysis of 168 patients. Annals of Surgery 1990, 212:173-177.
6. Shen P., Guenther J.M., Wanek L.A., Morton D.L. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?. Annals of Surgical Oncology 2000, 7:114-119.
7. Gamel J.W., George S.L., Edwards M.J., Seigler H.F. The long-term clinical course of patients with cutaneous melanoma. Cancer 2002, 95:1286-1293.
8. SEER cancer statistics review, 1975-2010 2012, Institute, N.C., Bethesda, MD. N. Howlader, A. Noone, M. Krapcho, J. Garshell, N. Neyman, S.F. Altekruse, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin (Eds.).
9. Mocellin S., Keilholz U., Rossi C.R., Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends in Molecular Medicine 2006, 12:130-139.
10. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews. Cancer 2008, 8:329-340.
11. Allard W.J., Matera J., Miller M.C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10:6897-6904.
12. Hunder N.N., Wallen H., Cao J., et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. New England Journal of Medicine 2008, 358:2698-2703.
13. Yee C., Thompson J.A., Byrd D., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:16168-16173.
14. Riker A., Cormier J., Panelli M., et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999, 126:112-120.
15. Jager E., Ringhoffer M., Altmannsberger M., et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. International Journal of Cancer. Journal international du cancer 1997, 71:142-147.
16. Mackensen A., Meidenbauer N., Vogl S., Laumer M., Berger J., Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2006, 24:5060-5069.
17. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:14608-14613.
18. Mehes G., Witt A., Kubista E., Ambros P.F. Circulating breast cancer cells are frequently apoptotic. American Journal of Pathology 2001, 159:17-20.
19. Fidler I.J. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine. Journal of the National Cancer Institute 1970, 45:773-782.
20. Ossowski L., Aguirre-Ghiso J.A. Dormancy of metastatic melanoma. Pigment Cell & Melanoma Research 2010, 23:41-56.
21. Klein O., Ebert L.M., Nicholaou T., et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:2507-2513.
22. Bajaj N.S., Watt C., Hadjiliadis D., et al. Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection. Transplant International: Official Journal of the European Society for Organ Transplantation 2010, 23:e26-e31.
23. Strauss D.C., Thomas J.M. Transmission of donor melanoma by organ transplantation. Lancet Oncology 2010, 11:790-796.
24. Buell J.F., Beebe T.M., Trofe J., et al. Donor transmitted malignancies. Annals of Transplantation: Quarterly of the Polish Transplantation Society 2004, 9:53-56.
25. Chen K.T., Olszanski A., Farma J.M. Donor transmission of melanoma following renal transplant. Case Reports in Transplantation 2012, 2012:764019.
26. MacKie R.M., Reid R., Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. New England Journal of Medicine 2003, 348:567-568.
27. Morris-Stiff G., Steel A., Savage P., et al. Transmission of donor melanoma to multiple organ transplant recipients. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeon 2004, 4:444-446.
28. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996, 61:274-278.
29. Freeman J.B., Gray E.S., Millward M., Pearce R., Ziman M. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine 2012, 10:192.
30. Carrillo E., Prados J., Marchal J.A., et al. Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients. Disease Markers 2006, 22:175-181.
31. Koyanagi K., Kuo C., Nakagawa T., et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clinical Chemistry 2005, 51:981-988.
32. Farthmann B., Eberle J., Krasagakis K., et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. Journal of Investigative Dermatology 1998, 110:263-267.
33. Mellado B., Colomer D., Castel T., et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1996, 14:2091-2097.
34. Schittek B., Bodingbauer Y., Ellwanger U., Blaheta H.J., Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. British Journal of Dermatology 1999, 141:30-36.
35. De Giorgi V., Pinzani P., Salvianti F., et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. Journal of Investigative Dermatology 2010, 130:2440-2447.
36. Rao C., Bui T., Connelly M., et al. Circulating melanoma cells and survival in metastatic melanoma. International Journal of Oncology 2011, 38:755-760.
37. Khoja L., Lorigan P., Zhou C., et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. Journal of Investigative Dermatology 2013, 133:1582-1590.
38. Koyanagi K., Mori T., O'Day S.J., Martinez S.R., Wang H.J., Hoon D.S. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Research 2006, 66:6111-6117.
39. Koyanagi K., O'Day S.J., Gonzalez R., et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005, 23:8057-8064.
40. Ghossein R.A., Coit D., Brennan M., et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1998, 4:419-428.
41. Hoshimoto S., Faries M.B., Morton D.L., et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Annals of Surgery 2012, 255:357-362.
42. Mellado B., Del Carmen Vela M., Colomer D., et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002, 20:4032-4039.
43. Mellado B., Gutierrez L., Castel T., et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1999, 5:1843-1848.
44. Clawson G.A., Kimchi E., Patrick S.D., et al. Circulating tumor cells in melanoma patients. PLoS ONE 2012, 7:e41052.
45. Osella-Abate S., Savoia P., Quaglino P., et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. British Journal of Cancer 2003, 89:1457-1462.
46. Rutkowski P., Nowecki Z.I., Kulik J., Ruka W., Siedlecki J.A. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. Melanoma Research 2008, 18:246-252.
47. de Vries T.J., Fourkour A., Punt C.J., Ruiter D.J., van Muijen G.N. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method. Melanoma Research 2000, 10:119-126.
48. Jung F.A., Buzaid A.C., Ross M.I., et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1997, 15:2826-2831.
49. Reinhold U., Berkin C., Bosserhoff A.K., et al. Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001, 19:1723-1727.
50. Liu Z., Fusi A., Klopocki E., et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. Journal of Translational Medicine 2011, 9:70.
51. Kitago M., Koyanagi K., Nakamura T., et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clinical Chemistry 2009, 55:757-764.
52. Khoja L., Shenjere P., Hodgson C., et al. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Research 2014, 24:40-46.
53. De Giorgi V., Pinzani P., Salvianti F., et al. Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Archives of Dermatology 2010, 146:1120-1124.
54. Itakura E., Huang R.R., Wen D.R., Cochran A.J. "Stealth" melanoma cells in histology-negative sentinel lymph nodes. American Journal of Surgical Pathology 2011, 35:1657-1665.
55. Benez A., Geiselhart A., Handgretinger R., Schiebel U., Fierlbeck G. Detection of circulating melanoma cells by immunomagnetic cell sorting. Journal of Clinical Laboratory Analysis 1999, 13:229-233.
56. Siewert C., Herber M., Hunzelmann N., et al. Rapid enrichment and detection of melanoma cells from peripheral blood mononuclear cells by a new assay combining immunomagnetic cell sorting and immunocytochemical staining. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2001, 158:51-60.
57. Georgieva J., Milling A., Orfanos C.E., Geilen C.C. Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. Melanoma Research 2002, 12:309-317.
58. Fusi A., Reichelt U., Busse A., et al. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. Journal of Investigative Dermatology 2011, 131:487-494.
59. Sakaizawa K., Goto Y., Kiniwa Y., et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. British Journal of Cancer 2012, 106:939-946.
60. Campoli M.R., Chang C.C., Kageshita T., Wang X., McCarthy J.B., Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Critical Reviews in Immunology 2004, 24:267-296.
61. Shih I.M., Elder D.E., Hsu M.Y., Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. American Journal of Pathology 1994, 145:837-845.
62. Xie S., Luca M., Huang S., et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Research 1997, 57:2295-2303.
63. Bardin N., Frances V., Lesaule G., Horschowski N., George F., Sampol J. Identification of the S-Endo 1 endothelial-associated antigen. Biochemical and Biophysical Research Communications 1996, 218:210-216.
64. Reid A.L., Millward M., Pearce R., et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. British Journal of Dermatology 2013, 168:85-92.
65. Schatton T., Frank M.H. Antitumor immunity and cancer stem cells. Annals of the New York Academy of Sciences 2009, 1176:154-169.
66. Chartrain M., Riond J., Stennevin A., et al. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS ONE 2012, 7:e36762.
67. Chen K.G., Szakacs G., Annereau J.P., et al. Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Research/Sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2005, 18:102-112.
68. Boiko A.D., Razorenova O.V., van de Rijn M., et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
69. Klein W.M., Wu B.P., Zhao S., Wu H., Klein-Szanto A.J., Tahan S.R. Increased expression of stem cell markers in malignant melanoma. Modern Pathology 2007, 20:102-107.
70. Kulik J., Nowecki Z.I., Rutkowski P., et al. Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. Melanoma Research 2001, 11:65-73.
71. Curry B.J., Myers K., Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1999, 17:2562-2571.
72. Hoon D.S., Wang Y., Dale P.S., et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1995, 13:2109-2116.
73. Reinhold U., Ludtke-Handjery H.C., Schnautz S., Kreysel H.W., Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. Journal of Investigative Dermatology 1997, 108:166-169.
74. Battayani Z., Grob J.J., Xerri L., et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Archives of Dermatology 1995, 131:443-447.
75. Quereux G., Denis M., Khammari A., Lustenberger P., Dreno B. Prognostic value of tyrosinase reverse-transcriptase polymerase chain reaction in metastatic melanoma. Dermatology (Basel, Switzerland) 2001, 203:221-225.
76. Samija I., Lukac J., Maric-Brozic J., Kusic Z. Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma. Croatian Medical Journal 2004, 45:142-148.
77. Brownbridge G.G., Gold J., Edward M., MacKie R.M. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled - polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. British Journal of Dermatology 2001, 144:279-287.
78. Alao J.P., Mohammed M.Q., Slade M.J., Retsas S. Detection of tyrosinase mRNA by RT-PCR in the peripheral blood of patients with advanced metastatic melanoma. Melanoma Research 1999, 9:395-399.
79. Sorensen B.S., Schmidt H., von der Maase H., Straten P.T., Nexo E. Quantification of melanoma cell-specific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR. Clinical Chemistry 2000, 46:1923-1928.
80. Muhlbauer M., Langenbach N., Stolz W., et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clinical Cancer Research 1999, 5:1099-1105.
81. de Vries T.J., Fourkour A., Punt C.J., et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. British Journal of Cancer 1999, 80:883-891.
82. Proebstle T.M., Jiang W., Hogel J., Keilholz U., Weber L., Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. British Journal of Cancer 2000, 82:118-123.
83. Brossart P., Schmier J.W., Kruger S., et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Research 1995, 55:4065-4068.
84. Hanekom G.S., Stubbings H.M., Johnson C.A., Kidson S.H. The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Research 1999, 9:465-473.
85. Smith B., Selby P., Southgate J., Pittman K., Bradley C., Blair G.E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-1229.
86. Battyani Z., Xerri L., Hassoun J., Bonerandi J.J., Grob J.J. Tyrosinase gene expression in human tissues. Pigment Cell Research/Sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1993, 6:400-405.
87. Mitropapas G., Nezos A., Halapas A., et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 2006, 44:1403-1409.
88. Foss A.J., Guille M.J., Occleston N.L., Hykin P.G., Hungerford J.L., Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. British Journal of Cancer 1995, 72:155-159.
89. Brossart P., Keilholz U., Willhauck M., Scheibenbogen C., Mohler T., Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. Journal of Investigative Dermatology 1993, 101:887-889.
90. Visus C., Andres R., Mayordomo J.I., et al. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Research 2007, 17:83-89.
91. Schittek B., Blaheta H.J., Florchinger G., Sauer B., Garbe C. Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction. British Journal of Dermatology 1999, 141:37-43.
92. Marincola F.M., Hijazi Y.M., Fetsch P., et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. Journal of Immunotherapy With Emphasis on Tumor Immunology: Official Journal of the Society for Biological Therapy 1996, 19:192-205.
93. Maeurer M.J., Gollin S.M., Martin D., et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. Journal of Clinical Investigation 1996, 98:1633-1641.
94. Kawakami Y., Eliyahu S., Sakaguchi K., et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. Journal of Experimental Medicine 1994, 180:347-352.
95. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
96. Ugurel S., Houben R., Schrama D., et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2007, 13:6344-6350.
97. Medic S., Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Critical Reviews in Biochemistry and Molecular Biology 2009, 44:85-97.
98. Medic S., Rizos H., Ziman M. Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochemical and Biophysical Research Communications 2011, 411:832-837.
99. Matsuzaki Y., Hashimoto S., Fujita T., et al. Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE). Journal of Immunotherapy (Hagerstown, Md.: 1997) 2005, 28:10-19.
100. Vachtenheim J., Novotna H. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. Cellular and Molecular Biology (Noisy-le-Grand, France) 1999, 45:1075-1082.
101. Koch S.E., Lange J.R. Amelanotic melanoma: the great masquerader. Journal of the American Academy of Dermatology 2000, 42:731-734.
102. Notani K., Shindoh M., Yamazaki Y., et al. Amelanotic malignant melanomas of the oral mucosa. British Journal of Oral & Maxillofacial Surgery 2002, 40:195-200.
103. Sarantou T., Chi D.D., Garrison D.A., et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Research 1997, 57:1371-1376.
104. Cheung W.L., Patel R.R., Leonard A., Firoz B., Meehan S.A. Amelanotic melanoma: a detailed morphologic analysis with clinicopathologic correlation of 75 cases. Journal of Cutaneous Pathology 2012, 39:33-39.
105. Takeuchi H., Morton D.L., Kuo C., et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2004, 22:2671-2680.
106. Takahashi T., Johnson T.D., Nishinaka Y., Morton D.L., Irie R.F. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. Journal of Investigative Dermatology 1999, 112:205-209.
107. Goto Y., Koyanagi K., Narita N., et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. Journal of Investigative Dermatology 2010, 130:221-229.
108. Javelaud D., Alexaki V.I., Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell & Melanoma Research 2008, 21:123-132.
109. Hoshimoto S., Shingai T., Morton D.L., et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. Journal of Clinical Oncology 2012, 30:3819-3826.
110. Palmieri G., Strazzullo M., Ascierto P.A., Satriano S.M., Daponte A., Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1999, 17:304-311.
111. Schrader A.J., Probst-Kepper M., Grosse J., et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Research 2000, 10:355-362.
112. Glaser R., Rass K., Seiter S., Hauschild A., Christophers E., Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1997, 15:2818-2825.
113. Osella Abate S., Savoia P., Cambieri I., Salomone B., Quaglino P., Bernengo M.G. Role of RT-PCR tyrosinase detection in the monitoring of patients with advanced metastatic melanoma. Melanoma Research 2000, 10:545-555.
114. Koyanagi K., O'Day S.J., Boasberg P., et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clinical Cancer Research: Official Journal of the American Association for Cancer Research 2010, 16:2402-2408.
115. Fusi A., Collette S., Busse A., et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). European Journal of Cancer (Oxford, England: 1990) 2009, 45:3189-3197.
116. Palmieri G., Satriano S.M., Budroni M., et al. Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer 2006, 6:266.
117. Steen S., Nemunaitis J., Fisher T., Kuhn J. Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proceedings (Baylor University. Medical Center) 2008, 21:127-132.
118. O'Brien C.M., Rood K.D., Bhattacharyya K., et al. Capture of circulating tumor cells using photoacoustic flowmetry and two phase flow. Journal of Biomedical Optics 2012, 17:061221.
119. Weight R.M., Dale P.S., Viator J.A. Detection of circulating melanoma cells in human blood using photoacoustic flowmetry. Conference proceedings:... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society 2009, 2009:106-109.
120. O'Brien C.M., Rood K., Sengupta S., et al. Detection and isolation of circulating melanoma cells using photoacoustic flowmetry. Journal of Visualized Experiments: JoVE 2011, e3559.
121. Fehm T., Muller V., Aktas B., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Research and Treatment 2010, 124:403-412.
122. Jin H.Y., Yamashita T., Minamitsuji Y., Omori F., Jimbow K. Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction. Journal of Dermatological Science 2003, 33:169-176.
123. Chelly J., Concordet J.P., Kaplan J.C., Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:2617-2621.
124. Kaplan J.-C., Kahn A., Chelly J. Illegitimate transcription: its use in the study of inherited disease. Human Mutation 1992, 1:357-360.
125. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
126. Grichnik J.M., Burch J.A., Schulteis R.D., et al. Melanoma, a tumor based on a mutant stem cell?. Journal of Investigative Dermatology 2006, 126:142-153.
127. Monzani E., Facchetti F., Galmozzi E., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. European Journal of Cancer (Oxford, England: 1990) 2007, 43:935-946.
128. Zabierowski S.E., Herlyn M. Melanoma stem cells: the dark seed of melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008, 26:2890-2894.
129. Fang D., Nguyen T.K., Leishear K., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research 2005, 65:9328-9337.
130. Chung J., Shao H., Reiner T., Issadore D., Weissleder R., Lee H. Microfluidic cell sorter (muFCS) for on-chip capture and analysis of single cells. Advanced Healthcare Materials 2012, 1:432-436.
131. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
132. Stott S.L., Hsu C.H., Tsukrov D.I., et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:18392-18397.
133. Nedosekin D.A., Sarimollaoglu M., Ye J.H., Galanzha E.I., Zharov V.P. In vivo ultra-fast photoacoustic flow cytometry of circulating human melanoma cells using near-infrared high-pulse rate lasers. Cytometry. Part A: The Journal of the International Society for Analytical Cytology 2011, 79:825-833.
134. Galanzha E.I., Shashkov E.V., Spring P.M., Suen J.Y., Zharov V.P. In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Research 2009, 69:7926-7934.
135. Petrov Y.Y., Petrova I.Y., Patrikeev I.A., Esenaliev R.O., Prough D.S. Multiwavelength optoacoustic system for noninvasive monitoring of cerebral venous oxygenation: a pilot clinical test in the internal jugular vein. Optics Letters 2006, 31:1827-1829.
136. Petrova I.Y., Esenaliev R.O., Petrov Y.Y., et al. Optoacoustic monitoring of blood hemoglobin concentration: a pilot clinical study. Optics Letters 2005, 30:1677-1679.
137. Wascher R.A., Morton D.L., Kuo C., et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2003, 21:2558-2563.
138. Rapanotti M.C., Bianchi L., Ricozzi I., et al. Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients. British Journal of Dermatology 2009, 160:338-344.
139. Bitisik O., Camlica H., Duranyildiz D., Tas F., Kurul S., Dalay N. Detection of circulating melanoma cells by a two-marker polymerase chain reaction assay in relation to therapy. Journal of Biochemistry and Molecular Biology 2003, 36:173-178.
140. Palmieri G., Ascierto P.A., Perrone F., et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2003, 21:767-773.
141. Palmieri G., Pirastu M., Strazzullo M., et al. Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2001, 158:200-203.
142. Quaglino P., Osella-Abate S., Cappello N., et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Research 2007, 17:75-82.
143. Osella-Abate S., Quaglino P., Savoia P., Leporati C., Comessatti A., Bernengo M.G. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Research 2002, 12:325-334.
144. Samija I., Lukac J., Maric-Brozic J., et al. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Research 2010, 20:293-302.
145. Konstantopoulos K., Psatha M., Kalotychou V., et al. Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients. Panminerva Medica 2001, 43:109-113.
146. Aubin F., Chtourou M., Teyssier J.R., et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Research 2000, 10:113-118.
147. O'Connell C.D., Juhasz A., Kuo C., Reeder D.J., Hoon D.S. Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence. Clinical Chemistry 1998, 44:1161-1169.
148. Voit C., Schoengen A., Schwurzer M., Weber L., Mayer T., Proebstle T.M. Detection of regional melanoma metastases by ultrasound B-scan, cytology or tyrosinase RT-PCR of fine-needle aspirates. British Journal of Cancer 1999, 80:1672-1677.
149. Pittman K., Burchill S., Smith B., et al. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 1996, 7:297-301.
150. Stevens G.L., Scheer W.D., Levine E.A. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 1996, 5:293-296.
151. Miyashiro I., Kuo C., Huynh K., et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clinical Chemistry 2001, 47:505-512.
152. Koyanagi K., O'Day S.J., Gonzalez R., et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clinical Cancer Research 2006, 12:1137-1143.
153. Fusi A., Liu Z., Kummerlen V., Nonnemacher A., Jeske J., Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. Journal of Translational Medicine 2012, 10:52.
154. Reynolds S.R., Albrecht J., Shapiro R.L., et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003, 9:1497-1502.